A recent study indicated that TGF‐β1, a key cytokine in scleroderma, up‐regulates glycolysis in dermal fibroblasts derived from SSc patients, and inhibition of glycolysis attenuates its pro‐fibrotic effects (59). Here, TGFB1 is linked to systemic sclerosis.